Literature DB >> 13679324

Thiazide diuretics and the risk for hip fracture.

Mariette W C J Schoofs1, Marjolein van der Klift, Albert Hofman, Chris E D H de Laet, Ron M C Herings, Theo Stijnen, Huibert A P Pols, Bruno H Ch Stricker.   

Abstract

BACKGROUND: Since most hip fractures are related to osteoporosis, treating accelerated bone loss can be an important strategy to prevent hip fractures. Thiazides have been associated with reduced age-related bone loss by decreasing urinary calcium excretion.
OBJECTIVE: To examine the association between dose and duration of thiazide diuretic use and the risk for hip fracture and to study the consequences of discontinuing use.
DESIGN: Prospective population-based cohort study.
SETTING: The Rotterdam Study. PARTICIPANTS: 7891 individuals 55 years of age and older. MEASUREMENTS: Hip fractures were reported by the general practitioners and verified by trained research assistants. Details of all dispensed drugs were available on a day-to-day basis. Exposure to thiazides was divided into 7 mutually exclusive categories: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days.
RESULTS: 281 hip fractures occurred. Relative to nonuse, current use of thiazides for more than 365 days was statistically significantly associated with a lower risk for hip fracture (hazard ratio, 0.46 [95% CI, 0.21 to 0.96]). There was no clear dose dependency. This lower risk disappeared approximately 4 months after thiazide use was discontinued.
CONCLUSIONS: Thiazide diuretics protect against hip fracture, but this protective effect disappears within 4 months after use is discontinued.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679324     DOI: 10.7326/0003-4819-139-6-200309160-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  50 in total

1.  Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies.

Authors:  Lili Ma; Ling Oei; Lindi Jiang; Karol Estrada; Huiyong Chen; Zhen Wang; Qiang Yu; Maria Carola Zillikens; Xin Gao; Fernando Rivadeneira
Journal:  Eur J Epidemiol       Date:  2012-03-27       Impact factor: 8.082

2.  Psychotropic medications and the risk of fracture: a meta-analysis.

Authors:  Bahi Takkouche; Agustín Montes-Martínez; Sudeep S Gill; Mahyar Etminan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs.

Authors:  Gerardo Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

Review 4.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

5.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

6.  Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.

Authors:  B H Ch Stricker; T Stijnen
Journal:  Eur J Epidemiol       Date:  2010-04-01       Impact factor: 8.082

7.  A susceptibility haplotype within the endothelial nitric oxide synthase gene influences bone mineral density in hypertensive women.

Authors:  Monica Singh; Puneetpal Singh; Surinder Singh; Pawan Kumar Juneja; Taranpal Kaur
Journal:  J Bone Miner Metab       Date:  2013-11-10       Impact factor: 2.626

8.  Gender difference in kidney electrolyte transport. I. Role of AT1a receptor in thiazide-sensitive Na+-Cl- cotransporter activity and expression in male and female mice.

Authors:  Jing Li; Ryo Hatano; Shuhua Xu; Laxiang Wan; Lei Yang; Alan M Weinstein; Lawrence Palmer; Tong Wang
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-31

Review 9.  Hyponatremia and bone disease.

Authors:  Armando Luis Negri; Juan Carlos Ayus
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

10.  Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.

Authors:  C Kruse; P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.